Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: UT-15C Clear all
Withdrawn Phase 2 Interventional

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT02603068
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Injectable Product, Riociguat Pill
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

NCT00004497
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
8 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
7
States / cities
Torrance, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

NCT01305252
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil inhalations, tadalafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
IV Remodulin, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
1 Hour to 14 Days
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325403
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

NCT02318758
View directory record Official record
Conditions
Healthy
Interventions
UT-15C, ethanol
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Three Times Daily Dosing of UT-15C

NCT01746485
View directory record Official record
Conditions
Healthy
Interventions
UT-15C
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension

NCT00887978
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C SR, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

NCT01481974
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
Treprostinil
Drug
Lead sponsor
Abhinav Humar, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

NCT02178566
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

NCT00373360
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

NCT00067041
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Remodulin (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
4
States / cities
Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 3, 2026, 5:13 AM EDT
Withdrawn Phase 2 Interventional

Telemonitoring to Treat Group 2 Pulmonary Hypertension

NCT04882774
View directory record Official record
Conditions
Pulmonary Hypertension Due to Left Heart Disease
Interventions
Treprostinil Diolamine
Drug
Lead sponsor
Mardi Gomberg -Maitland MD, MSc
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

NCT04708782
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Terminated Phase 4 Interventional Results available

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

NCT00643604
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 3, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

NCT01560637
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C (treprostinil diolamine)
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325442
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) sustained release tablets, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 3, 2026, 5:13 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

NCT01477333
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C SR, Tyvaso Inhalation Solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 3, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 3, 2026, 5:13 AM EDT